Albumin paclitaxel is named as a drug or biological intervention in 19 clinical trials in our China trial register, 13 of which are recruiting. Lead sponsors include Chipscreen Biosciences, Ltd. (2), Peking University Cancer Hospital & Institute (1) and Fudan University (1). Registered phases: Phase 2, Phase 3, Phase 1, Observational, Phase 1/2 and Phase 4. Conditions studied include Breast Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 2 |
| Metastatic Pancreatic Ductal Adenocarcinoma | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| Paget Disease, Extramammary | 1 |
| Rhabdomyosarcoma | 1 |
| Testicular Cancer | 1 |
| Penile Cancer | 1 |
| Triple-negative Breast Cancer | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| HER2-low Breast Cancer | 1 |
| Immunotherapy Esophagus Cancer | 1 |
| Oral Squamous Cell Carcinoma | 1 |
| Early-Stage Oral Squamous Cell Carcinoma | 1 |
| Gastric Cancer | 1 |
| Locally Advanced Pancreatic Cancer | 1 |
| HER2-positive Breast Cancer | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Advanced and Metastatic NSCLC | 1 |
| Hematologic Malignancy | 1 |
| Solid Tumor | 1 |
| Esophageal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Chipscreen Biosciences, Ltd. | 2 |
| Peking University Cancer Hospital & Institute | 1 |
| Fudan University | 1 |
| Shanghai Junshi Bioscience Co., Ltd. | 1 |
| Peking Union Medical College | 1 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Fuzhou General Hospital | 1 |
| Weijia Fang, MD | 1 |
| Jun Jia | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Sun Yat-sen University | 1 |
| Henan Cancer Hospital | 1 |
| Peking University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| Xijing Hospital | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| Register | Albumin paclitaxel trials |
|---|---|
| Clinical trials in China | 19 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Albumin paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Albumin paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.